Safety and tolerability of intravitreal umedaptanib pegol (anti-FGF2) for neovascular age-related macular degeneration (nAMD): a phase 1, open-label study

Eye, Published online: 01 December 2023; doi:10.1038/s41433-023-02849-6Safety and tolerability of intravitreal umedaptanib pegol (anti-FGF2) for neovascular age-related macular degeneration (nAMD): a phase 1, open-label study

https://www.nature.com/articles/s41433-023-02849-6

Source: Eye - December 1, 2023 Category: Opthalmology Authors: Daniel S. Pereira Kazumasa Akita Robert B. Bhisitkul Toshiaki Nishihata Yusuf Ali Emiko Nakamura Yoshikazu Nakamura Source Type: research

More News: Age-Related Macular Degeneration (AMD) | Opthalmology | Study